Related Experiment Video
Updated: May 15, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
Published on: August 25, 2017
Malignant atrophic papulosis (Köhlmeier-Degos disease) - a review
Athanasios Theodoridis1, Evgenia Makrantonaki, Christos C Zouboulis
1Departments of Dermatology, Venerology, Allergology and Immunology, Dessau Medical Center, Auenweg 38, Dessau, 06847, Germany.
Unlabelled:
DEFINITION OF THE DISEASE: Malignant atrophic papulosis (MAP), described independently by Köhlmeier and Degos et al., is a rare, chronic, thrombo-obliterative vasculopathy characterized by papular skin lesions with central porcelain-white atrophy and surrounding teleangiectatic rim.
Epidemiology:
Less than 200 cases have been described in the literature. The first manifestation of MAP usually occurs between the 20th and 50th year of life.
Clinical Description:
The cutaneous clinical picture is almost pathognomonic. The histology is not consistent but in most cases it shows a wedge-shaped connective tissue necrosis in the deep corium due to a thrombotic occlusion of the small arteries. In the systemic variant, manifestations mostly occur at the intestine and central nervous system.
Etiology:
The etiopathogenesis of the disease remains unknown, a genetic predisposition may occur. Vasculitis, coagulopathy or primary dysfunction of the endothelial cells have been implicated.
Diagnostic Methods:
Diagnosis is only based on the characteristic skin lesions. DIFFERRENTIAL DIAGNOSIS: It depends on the clinical presentation of MAP, but systemic lupus erythematosus and other connective tissue diseases need to be considered.
Management:
No effective treatment exists for the systemic manifestations, while compounds that facilitate blood perfusion have achieved a partial regression of the skin lesions in single cases.
Prognosis:
An apparently idiopathic, monosymptomatic, cutaneous, benign variant and a progressive, visceral one with approx. 50% lethality within 2-3 years have been reported. Systemic manifestations can develop years after the occurrence of skin lesions leading to bowel perforation and peritonitis, thrombosis of the cerebral arteries or massive intracerebral hemorrhage, meningitis, encephalitis, radiculopathy, myelitis.
Insights
Malignant atrophic papulosis (MAP) is a rare vasculopathy with characteristic skin lesions. While cutaneous MAP may be benign, systemic involvement can be fatal, highlighting the need for early diagnosis and management.
Area of Science:
- Dermatology
- Vascular Medicine
- Pathology
Background:
- Malignant atrophic papulosis (MAP) is a rare thrombo-obliterative vasculopathy affecting fewer than 200 individuals.
- Typically manifests between ages 20 and 50, with initial presentation often involving characteristic skin lesions.
Purpose of the Study:
- To define the characteristics, diagnosis, and prognosis of Malignant atrophic papulosis (MAP).
- To differentiate between benign cutaneous and progressive visceral forms of MAP.
Main Methods:
- Diagnosis relies on pathognomonic cutaneous lesions and characteristic histology showing connective tissue necrosis.
- Differential diagnosis includes systemic lupus erythematosus and other connective tissue diseases.
Main Results:
- No effective treatment for systemic MAP; blood perfusion enhancers show partial skin lesion regression.
- Systemic manifestations, including gastrointestinal and central nervous system involvement, can occur years after skin lesions.
Conclusions:
- MAP presents as a benign cutaneous form or a progressive visceral form with approximately 50% lethality within 2-3 years.
- Systemic involvement can lead to severe complications such as bowel perforation, cerebral thrombosis, or hemorrhage.
Related Concept Videos
Gastritis II: Pathophysiology
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease II: Pathophysiology
Inflammatory Bowel Disease III: Crohn's Disease
